ArriVent Biopharma Files Amendment to S-1 Registration Statement

TL;DR

<b>ArriVent Biopharma, Inc. has filed an amendment to its S-1 registration statement, indicating progress towards a public offering.</b>

AI Summary

ArriVent Biopharma, Inc. (AVBP) filed a Amended IPO Registration (S-1/A) with the SEC on January 22, 2024. ArriVent Biopharma, Inc. filed an amendment (S-1/A) to its registration statement on January 22, 2024. The filing is in accordance with the Securities Act of 1933, with registration number 333-276397. The company's principal executive offices are located at 18 Campus Boulevard, Suite 100, Newtown Square, PA 19073. The CEO is Zhengbin (Bing) Yao, Ph.D. The filing indicates the company is in the Pharmaceutical Preparations industry (SIC code 2834).

Why It Matters

For investors and stakeholders tracking ArriVent Biopharma, Inc., this filing contains several important signals. This amendment suggests ArriVent is moving forward with its plans to become a publicly traded company, which could provide capital for its biopharmaceutical development. The S-1 filing is a crucial step for any company seeking to raise capital through an IPO, detailing its business, financial condition, and risks to potential investors.

Risk Assessment

Risk Level: low — ArriVent Biopharma, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, not a new offering or financial report, thus carrying minimal immediate risk.

Analyst Insight

Monitor for the effectiveness of the registration statement and subsequent IPO pricing for potential investment opportunities.

Key Numbers

• 333-276397 — Registration Number (S-1/A Registration Statement)
• 2024-01-22 — Filing Date (Amendment No. 1 to Form S-1)
• 19073 — ZIP Code (Business Address)
• 2834 — SIC Code (Pharmaceutical Preparations)

Key Players & Entities

• ArriVent Biopharma, Inc. (company) — Registrant
• 2024-01-22 (date) — Filing date
• 333-276397 (registration_number) — Registration No.
• 1933 Act (regulation) — Securities Act of 1933
• Zhengbin (Bing) Yao, Ph.D. (person) — Chief Executive Officer
• Newtown Square, PA (location) — Business address
• 2834 (industry_code) — Primary Standard Industrial Classification Code Number
• John T. Rudy (person) — Copies to

Forward-Looking Statements

• ArriVent Biopharma, Inc. will complete its initial public offering. (ArriVent Biopharma, Inc.) — high confidence, target: Q1 2024
• The company's stock will begin trading on a major exchange. (ArriVent Biopharma, Inc.) — medium confidence, target: Q1 2024

FAQ

Industry Context

ArriVent Biopharma operates in the pharmaceutical preparations sector, focusing on the development of new drugs.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

1. Review the full S-1/A filing for detailed business operations and financial disclosures.
2. Track the SEC's review process and any further amendments to the registration statement.
3. Monitor for the effectiveness declaration of the registration statement, signaling readiness for an IPO.

Key Dates

• 2024-01-22: Filing of Amendment No. 1 to Form S-1 — Indicates progress in the registration process for a public offering.

Year-Over-Year Comparison

This is an amendment to a previously filed registration statement, indicating ongoing procedural steps rather than a new financial period's results.

Key Financial Figures

• $17.00 — ffering price per share will be between $17.00 and $19.00. We have applied to list our
• $19.00 — ce per share will be between $17.00 and $19.00. We have applied to list our common sto
• $3.1 billion — by Horizon Therapeutics plc in 2021 for $3.1 billion. Prior to Viela, Dr. Yao served as Seni

Filing Documents

• tm2321853-14_s1a.htm (S-1/A) — 3317KB
• tm2321853d16_ex1-1.htm (EX-1.1) — 180KB
• tm2321853d16_ex5-1.htm (EX-5.1) — 10KB
• tm2321853d16_ex10-3.htm (EX-10.3) — 232KB
• tm2321853d16_ex10-4.htm (EX-10.4) — 54KB
• tm2321853d16_ex23-1.htm (EX-23.1) — 2KB
• tm2321853d16_ex-filingfees.htm (EX-FILING FEES) — 20KB
• lg_arrivent-4c.jpg (GRAPHIC) — 12KB
• bc_stagedev-4c.jpg (GRAPHIC) — 77KB
• tb_patient-4c.jpg (GRAPHIC) — 57KB
• pc_cancercases-4c.jpg (GRAPHIC) — 51KB
• pc_confidential-4c.jpg (GRAPHIC) — 32KB
• tb_agents-4c.jpg (GRAPHIC) — 63KB
• fc_egfr-4c.jpg (GRAPHIC) — 82KB
• tb_drug-4c.jpg (GRAPHIC) — 31KB
• fc_cohort-4c.jpg (GRAPHIC) — 84KB
• fc_arm-4c.jpg (GRAPHIC) — 116KB
• lc_plasamconcent-4c.jpg (GRAPHIC) — 55KB
• lc_invivo01-4c.jpg (GRAPHIC) — 39KB
• lc_invivo02-4c.jpg (GRAPHIC) — 37KB
• lc_baf301-4c.jpg (GRAPHIC) — 35KB
• lc_baf302-4c.jpg (GRAPHIC) — 40KB
• lc_baf303-4clr.jpg (GRAPHIC) — 38KB
• lc_baf304-4c.jpg (GRAPHIC) — 41KB
• tb_treatment-4c.jpg (GRAPHIC) — 66KB
• tb_confirmedorr-4c.jpg (GRAPHIC) — 106KB
• bc_treatment-4c.jpg (GRAPHIC) — 76KB
• bc_treated-4clr.jpg (GRAPHIC) — 85KB
• tb_overviewtrae-4c.jpg (GRAPHIC) — 79KB
• tb_preferred-4c.jpg (GRAPHIC) — 77KB
• fc_combination-4c.jpg (GRAPHIC) — 73KB
• tb_character-4c.jpg (GRAPHIC) — 57KB
• lc_median-4clr.jpg (GRAPHIC) — 67KB
• fc_acrylamide-4clr.jpg (GRAPHIC) — 57KB
• ph_egfr-4c.jpg (GRAPHIC) — 113KB
• tm2321853d16_ex5-1img002.jpg (GRAPHIC) — 2KB
• tm2321853d16_ex5-1img001.jpg (GRAPHIC) — 1KB
• 0001104659-24-005364.txt (&nbsp;) — 6194KB

RISK FACTORS

RISK FACTORS 13 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 87 MARKET AND INDUSTRY DATA 89

USE OF PROCEEDS

USE OF PROCEEDS 90 DIVIDEND POLICY 92 CAPITALIZATION 93

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 98

BUSINESS

BUSINESS 113 MANAGEMENT 163 EXECUTIVE AND DIRECTOR COMPENSATION 171 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 182 PRINCIPAL STOCKHOLDERS 185

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 188 SHARES ELIGIBLE FOR FUTURE SALE 194 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 197

UNDERWRITING

UNDERWRITING 202 LEGAL MATTERS 211 EXPERTS 211 WHERE YOU CAN FIND MORE INFORMATION 211 Index to Financial Statements F-1 We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. "ArriVent" and our logo are our trademarks. All other service marks, trademarks and trade names appearing in this prospectus are the property of their respective owners. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. Solely for convenience, trademarks and tradenames referred to in this prospectus may appear without the or symbols, but such r

View Full Filing

View this S-1/A filing on SEC EDGAR